ArticleNature2022
PD-1 combination therapy with IL-2 modifies CD8
Open access · greenAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 224 papers.
0numbers the graph read from it
0cells of the map it votes in
224citing papers in PubMed
24.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
224 citing papers in PubMed, 299 citations in OpenAlex.
- Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell reports. Medicine · 2024Trial
- In Vitro Inhibition of STAT5 Signaling Limits CD8+ T-cell Exhaustion and Improves Outcomes in Adoptive T-cell Therapy.Cancer immunology research · 2026Article
- IL-2/CD25 acts within the tumor microenvironment to reprogram tumor-specific cytotoxic CD8Journal for immunotherapy of cancer · 2026Article
- Article
- Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.Science advances · 2026Article
- A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.ACS central science · 2026Article
- Metalloimmunological hydrogel-based cancer vaccine potentiates postoperative tumor immunotherapy.Nature communications · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
- Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.Journal of virology · 2026Article
- CD25 genetic ablation on lymphoid cell lines to obtain models of stimulation through the Interleukin-2 beta/gamma receptor.Scientific reports · 2026Article
- ATF7ip Inhibits the Tumor Immune Response by Promoting Terminal CD8+ T-cell Exhaustion.Cancer immunology research · 2026Article
- Coordinated post-transcriptional regulation facilitates PD-L1 protein production and tumor immune suppression.Cancer letters · 2026Article
- Adaptive resistance in cancer immunotherapy.Cellular & molecular immunology · 2026Review
- New insights into progenitor exhausted T cell populations.Nature reviews. Immunology · 2026Article
- Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8BMC medicine · 2026Article
- PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer.JCI insight · 2026Article
- Targeting tumor-specific T cells with LAG3-directed interleukin-2 prevents T-cell exhaustion and reinvigorates antitumor immunity.Signal transduction and targeted therapy · 2026Article
- T Cell Exhaustion as a Regulated Differentiation Programme.European journal of immunology · 2026Review
- The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance.Translational lung cancer research · 2026Review
- MicroRNA-29a enhances and preserves stem-like CD8 T cell differentiation by regulating master epigenetic circuits of exhaustion.bioRxiv : the preprint server for biology · 2026Article
164 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors at 12 institutions in 3 countries.
Masao HashimotoEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7120-1390
Koichi ArakiEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Maria A CardenasDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-8566-9576
Peng LiLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4721-5936
Rohit R JadhavDepartment of Immunology, Mayo Clinic School of Medicine and Sciences, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-2999-6329
Haydn T KissickEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7624-5598
William H HudsonEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-2513-1213
Donald J McGuireEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Rebecca C ObengEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8624-7108
Andreas WielandEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9648-7922
Judong LeeEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-7064-1079
Daniel T McManusEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
James L RossEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Se Jin ImEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Junghwa LeeEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
Jian-Xin LinLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Bin HuDepartment of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-0836-0935
Erin E WestLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.
Christopher D ScharerDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-7716-8504
Gordon J FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7210-5616
Arlene H SharpeDepartment of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9736-2109
Suresh S RamalingamWinship Cancer Institute, Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-0757-3106
Alex PellerinBiogen, Cambridge, MA, USA.
Volker TeichgräberRoche Innovation Center Basel, Basel, Switzerland.
William J GreenleafDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-1409-3095
Christian KleinRoche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-7594-7280
Jorg J GoronzyDepartment of Immunology, Mayo Clinic School of Medicine and Sciences, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-7670-1856
Pablo UmañaRoche Innovation Center Zurich, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-8206-2771
Warren J LeonardLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5740-7448
Kendall A SmithDepartment of Medicine, Division of Immunology, Weill Medical College of Cornell University, New York, NY, USA.ORCID http://orcid.org/0000-0002-6759-550X
Rafi AhmedEmory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA. rahmed@emory.edu.ORCID http://orcid.org/0000-0002-9591-2621
Emory University · USNational Institutes of Health · USRoche (Switzerland) · CHMayo Clinic · USStanford University · USBiogen (United States) · USBrigham and Women's Hospital · USCincinnati Children's Hospital Medical Center · USCornell University · USEmory Healthcare · USHarvard University · USNorthwestern University · US
Funding
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MVACCINE INDUCED IMMUNITY IN THE YOUNG AND AGEDU19AI057266 · NIAID · EMORY UNIVERSITY · PI Rafi Ahmed · 2003 to 2026
$81.7MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MWinship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MTransgenic/KnockoutP01AI056299 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI FREEMAN, GORDON JAMES · 2003 to 2023
$42.5MUnderstanding and Overcoming T cell Immunosuppression in GlioblastomaP01CA236749 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI E. Antonio Chiocca · 2020 to 2026
$19.5MProject 3: Targeting Bax signaling to overcome treatment resistance in NSCLCP50CA217691 · NCI · EMORY UNIVERSITY · PI SICA, GABRIEL LARKIN · 2019 to 2024
$10.1MT CELL MEMORY TO VIRUSESR01AI030048 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AHMED, RAFI · 1990 to 2022
$5.2MMemory T Cell Development and Survival in T Cell Responses of Older IndividualsR01AI129191 · NIAID · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI GORONZY, JORG J · 2017 to 2021
$1.9MControl of CD8+ T cell exhaustion by novel checkpoint moleculesR00AI153736 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI HUDSON, WILLIAM HARRIS · 2022 to 2023
$498kNCI NIH HHS P01 CA236749NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA060553NCI NIH HHS P30 CA138292NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA217691NIAID NIH HHS K99 AI153736NIAID NIH HHS P01 AI056299NIAID NIH HHS R00 AI153736NIAID NIH HHS R01 AI030048NIAID NIH HHS R01 AI129191NIAID NIH HHS U19 AI057266NIH HHS P51 OD011132
Abstract
Combination therapy with PD-1 blockade and IL-2 is highly effective during chronic lymphocytic choriomeningitis virus infection
Indexed as
CD8-Positive T-LymphocytesInterleukin-2Programmed Cell Death 1 ReceptorCell DifferentiationDrug Therapy, CombinationHumansInterleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma SubunitLymphocytic ChoriomeningitisT Cell Transcription Factor 1Interleukin-2Interleukin-2 Receptor alpha SubunitInterleukin-2 Receptor beta SubunitInterleukin Receptor Common gamma SubunitProgrammed Cell Death 1 ReceptorT Cell Transcription Factor 1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.